Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 2,210 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Radiation Treatment for Tumors Clear all

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Stereotactic Body Radiation Therapy (SBRT); Combination Product
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Recurrent Glioblastoma, Recurrent Gliomas
Interventions: Device :DaRT seeds; Device
Lead sponsor: Alpha Tau Medical LTD.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Scottsdale, Arizona • New York, New York • Columbus, Ohio

Conditions: Lymphoma, Hodgkin Disease, Lymphoma, Hodgkin Disease, Lymphoma: Hodgkin
Interventions: Vincristine, Cyclophosphamide, Doxorubicin, Prednisone, Bleomycin, Etoposide, Low-dose radiotherapy (RT); Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2017
U.S. locations: 2
States / cities: Stanford, California • Vallejo, California

Conditions: Head and Neck Carcinoma, Head and Neck Lymph Node, Head and Neck Squamous Cell Carcinoma, Laryngeal Neoplasm, Radiation Therapy Recipient
Interventions: Photoacoustic Imaging, Transcutaneous Acupoint Electrical Stimulation; Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate, Progressive mCRPC
Interventions: I-131-1095, Enzalutamide; Drug
Lead sponsor: Progenics Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 20
States / cities: Duarte, California • Los Angeles, California • Newport Beach, California + 15 more

Conditions: Head and Neck Squamous Cell Carcinoma, Malignant Head and Neck Neoplasm
Interventions: Medical Device Qardio® smart scale Usage and Evaluation, Questionnaire Administration; Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 2
States / cities: Rockville, Maryland • Portland, Oregon

Conditions: Brain Metastases
Interventions: Temozolomide, Valproic Acid, Whole Brain Radiation Therapy; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Pembrolizumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Dallas, Texas

Conditions: Breast Cancer
Interventions: Atezolizumab, Stereotactic radiosurgery (SRS); Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pancreatic Cancer
Interventions: TNFerade; Genetic
Lead sponsor: GenVec; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: La Jolla, California • Los Angeles, California • Orange, California + 20 more

Conditions: Non-small Cell Lung Cancer
Interventions: thermal ablation with external beam radiation; Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Prostate Cancer, Sexual Dysfunction
Interventions: Tadalafil, Placebo; Drug · Other
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 183
States / cities: Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 151 more

Conditions: Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Oligoprogressive, Progression
Interventions: Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Glioblastoma Multiforme
Interventions: Lucanthone, Temozolomide (TMZ), Radiation, Placebo; Drug · Radiation
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: La Jolla, California • Orange, California • Amherst, New York + 2 more

Conditions: Lung Cancer
Interventions: Hatha Yoga, Questionnaires, Walk Test; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Carcinoma
Interventions: Biospecimen Collection, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy Treatment Planning and Simulation; Procedure · Radiation · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Scottsdale, Arizona • Jacksonville, Florida

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomography, Stereotactic Body Radiation Therapy; Procedure · Radiation · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Duarte, California

Conditions: Salivary Gland Dysfunction, Xerostomia, Head and Neck Cancer
Interventions: Everolimus, Laboratory Biomarker Analysis, Survey Administration; Drug · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Aplastic Anemia, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Malignant Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Fludarabine, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Tacrolimus, Mycophenolate mofetil, Laboratory Biomarker Analysis; Drug · Radiation · Biological + 2 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Head and Neck Cancer
Interventions: Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy), Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site)., Nivolumab 3 mg/kg IV q2 weeks, Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).; Radiation · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Pancreatic Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 106
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more

Conditions: Depression, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: telephone-based intervention, screening questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications, psychosocial assessment and care; Behavioral · Other · Procedure
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 21 Years and older
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 16
States / cities: Alton, Illinois • Grand Rapids, Michigan • Springfield, Missouri + 10 more

Conditions: Merkel Cell Carcinoma, Skin Cancer
Interventions: Nivolumab, Ipilimumab, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 2
States / cities: Tampa, Florida • Columbus, Ohio

Conditions: Rectal Cancer
Interventions: Radiation, Aflibercept, Surgery, FOLFOX6; Radiation · Drug · Procedure
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 11
States / cities: Fort Myers, Florida • Pensacola, Florida • St. Petersburg, Florida + 8 more

Search by objective public record fields.

A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

Pembrolizumab in HNSCC With Residual Disease After Radiation

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Thermal Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer > 3.5 cm in Size

Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

Yoga Program for Lung Cancer Patients and Caregivers

Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer

Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas

Depression Screening in Patients Undergoing Radiation Therapy For Cancer

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer